Literature DB >> 2771479

Mucolipidosis II: correlation between radiological features and histopathology of the bones.

U E Pazzaglia1, G Beluffi, J B Campbell, E Bianchi, N Colavita, F Diard, P Gugliantini, U Hirche, K Kozlowski, A Marchi.   

Abstract

Twelve cases of Mucolipidosis II (I-cell disease) with a wide range of severity of skeletal involvement were studied. Pathological findings in two cases provided helpful information in understanding the radiographic features of dysostosis multiplex. Inhibition of the growth plate cartilage calcification and rickets-like lesions were observed in the metaphyses. Enhanced subperiosteal remodelling and paratrabecular fibrosis were also evident in the diaphyses. High levels of parathormone were found in one case. This finding supports the hypothesis that bone lesions may be secondary, at least in part, to damage in such viscera as the kidney and/or the liver and that they are mediated by vitamin D and parathormone.

Entities:  

Mesh:

Year:  1989        PMID: 2771479     DOI: 10.1007/BF02387638

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  20 in total

1.  Fetal mucolipidosis II (I-cell disease): radiologic and pathologic correlation.

Authors:  D S Babcock; K E Bove; G Hug; P S Dignan; S Soukup; N S Warren
Journal:  Pediatr Radiol       Date:  1986

2.  I-cell disease, mucolipidosis II. Pathological, histochemical, ultrastructural and biochemical observations in four cases.

Authors:  E F Gilbert; G Dawson; G M zu Rhein; J M Opitz
Journal:  Z Kinderheilkd       Date:  1973

3.  I-cell disease: a clinical picture.

Authors:  J G Leroy; J W Spranger; M Feingold; J M Opitz; A C Crocker
Journal:  J Pediatr       Date:  1971-09       Impact factor: 4.406

4.  [Mucolipidosis type II (inclusion cell disease). Study of a case and review of the literature].

Authors:  G de Montis; P Garnier; N Thomassin; J C Job; A Rossier
Journal:  Ann Pediatr (Paris)       Date:  1972-05-02

5.  Roentgenographic manifestations of Leroy's I-cell disease.

Authors:  P Taber; M T Gyepes; M Philippart; S Ling
Journal:  Am J Roentgenol Radium Ther Nucl Med       Date:  1973-05

6.  [Type II mucolipidosis].

Authors:  P Maroteaux; M C Hors-Cayla; J Pont
Journal:  Presse Med       Date:  1970-01-24       Impact factor: 1.228

7.  [Mucolipidosis Type II. STudy of 2 familial cases. Clinical and biochemical aspects].

Authors:  A Joannard; M Bost; J Pont; M Dieterlen; P Frappat; A Beaudoing
Journal:  Pediatrie       Date:  1974-12

8.  I-cell disease. Report of three cases.

Authors:  Y Terashima; K Tsuda; S Isomura; Y Sugiura; H Nogami
Journal:  Am J Dis Child       Date:  1975-09

9.  Neonatal mucolipidosis II (I-cell disease): clinical and radiologic features in three cases.

Authors:  H B Patriquin; P Kaplan; H P Kind; A Giedion
Journal:  AJR Am J Roentgenol       Date:  1977-07       Impact factor: 3.959

10.  Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats.

Authors:  R Schenk; W A Merz; R Mühlbauer; R G Russell; H Fleisch
Journal:  Calcif Tissue Res       Date:  1973-03-12
View more
  10 in total

1.  The natural history and osteodystrophy of mucolipidosis types II and III.

Authors:  Grace David-Vizcarra; Julie Briody; Jenny Ault; Michael Fietz; Janice Fletcher; Ravi Savarirayan; Meredith Wilson; Jim McGill; Matthew Edwards; Craig Munns; Melanie Alcausin; Sara Cathey; David Sillence
Journal:  J Paediatr Child Health       Date:  2010-03-29       Impact factor: 1.954

2.  The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.

Authors:  C Robinson; N Baker; J Noble; A King; G David; D Sillence; P Hofman; T Cundy
Journal:  J Inherit Metab Dis       Date:  2002-12       Impact factor: 4.982

3.  Disruption of the Man-6-P targeting pathway in mice impairs osteoclast secretory lysosome biogenesis.

Authors:  Eline van Meel; Marielle Boonen; Haibo Zhao; Viola Oorschot; F Patrick Ross; Stuart Kornfeld; Judith Klumperman
Journal:  Traffic       Date:  2011-05-05       Impact factor: 6.215

4.  Mucolipidosis II presenting as severe neonatal hyperparathyroidism.

Authors:  Sheila Unger; David A Paul; Michelle C Nino; Charles P McKay; Stephen Miller; Etienne Sochett; Nancy Braverman; Joe T R Clarke; David E C Cole; Andrea Superti-Furga
Journal:  Eur J Pediatr       Date:  2004-12-03       Impact factor: 3.183

5.  Neonatal mucolipidosis 2. The spontaneous evolution of early bone lesions and the effect of vitamin D treatment. Report of two cases.

Authors:  U E Pazzaglia; G Beluffi; C Danesino; P V Frediani; G Pagani; G Zatti
Journal:  Pediatr Radiol       Date:  1989

6.  Early characteristic radiographic changes in mucolipidosis II.

Authors:  Lillian M Lai; Ralph S Lachman
Journal:  Pediatr Radiol       Date:  2016-08-15

7.  I-Cell Disease (Mucolipidosis II) Presenting as Neonatal Fractures: A Case for Continued Monitoring of Serum Parathyroid Hormone Levels.

Authors:  Aneal Khan; Josephine Ho; Amy Pender; Xingchang Wei; Murray Potter
Journal:  Clin Pediatr Endocrinol       Date:  2008-08-08

8.  Secondary Hyperparathyroidism in Children with Mucolipidosis Type II (I-Cell Disease): Irish Experience.

Authors:  Ritma Boruah; Ahmad Ardeshir Monavari; Tracey Conlon; Nuala Murphy; Andreea Stroiescu; Stephanie Ryan; Joanne Hughes; Ina Knerr; Ciara McDonnell; Ellen Crushell
Journal:  J Clin Med       Date:  2022-03-02       Impact factor: 4.241

9.  A case of I-cell disease (mucolipidosis II) presenting with short femurs on prenatal ultrasound and profound diaphyseal cloaking.

Authors:  Thomas Capobres; Gauravi Sabharwal; Brent Griffith
Journal:  BJR Case Rep       Date:  2016-07-28

10.  Hip Morphology in Mucolipidosis Type II.

Authors:  Luise Sophie Ammer; Esmeralda Oussoren; Nicole Maria Muschol; Sandra Pohl; Maria Estela Rubio-Gozalbo; René Santer; Ralf Stuecker; Eik Vettorazzi; Sandra Rafaela Breyer
Journal:  J Clin Med       Date:  2020-03-08       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.